Cassava Sciences Announces Fireside Chat and Presentation Tuesday, April 5th
– CEO Remi Barbier to Discuss Q1 2022 Clinical and Corporate Updates – – Stakeholders…
News
Prof. Avi Schroeder Joins SciSparc’s Scientific Advisory Board to Support the Company’s Development of SCI-160 for Treating Pain
Prof. Schroeder to advise on SCI-160 formulation development to enhance biological effect and extended effect…
Shockwave Medical Announces Japanese Regulatory Approval of Coronary IVL
Transformative Shockwave C2 Intravascular Lithotripsy Catheter Will Soon Be Available in One of the World’s…
IBN (InvestorBrandNetwork) Coverage Initiated for Silo Pharma Inc.
NEW YORK, March 30, 2022 (GLOBE NEWSWIRE) — via InvestorWire – Silo Pharma Inc. (OTCQB:…
VectivBio Announces Japan License Deal and Loan Facility Agreement, Providing up to $117 Million to Fuel the Company Through Key Catalysts
Exclusive License with Asahi Kasei Pharma to develop and commercialize Apraglutide in Japan includes $30…
Acer Therapeutics Enrolls First Patient in its Phase 2a Clinical Trial of ACER-801 for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause
Results anticipated in H2 2022 NEWTON, Mass., March 30, 2022 (GLOBE NEWSWIRE) — Acer Therapeutics…
CytoDyn to Hold Webcast to Provide Company Update
VANCOUVER, Washington, March 30, 2022 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the…
Collegium Announces Master Settlement Agreement Resolving Pending Opioid-Related Litigation
STOUGHTON, Mass., March 30, 2022 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced…
INmune Bio, Inc. Announces Company’s CSO Dr. Mark Lowdell to Co-Host the “NK Cells in Solid Tumors” Workshop at Innate Killer Summit
The Company also Plans on Sharing INKmune™ Patient Case Studies Boca Raton, Florida, March 30,…
Universe Pharmaceuticals INC Announces Strategic Partnership with Lian-Ou Health to Develop its Digital Marketing and Sales on E-Commerce Platforms
Ji’an, Jiangxi, China, March 30, 2022 (GLOBE NEWSWIRE) — Universe Pharmaceuticals INC (the “Company”) (Nasdaq:…
Morphic to Participate in BMO Inflammation and Immunology Spotlight Series Panel
WALTHAM, Mass., March 30, 2022 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company…
PepGen Continues to Build Leadership Team with Additions of Senior Vice President, Clinical Operations and Vice President, Toxicology
BOSTON, March 30, 2022 (GLOBE NEWSWIRE) — PepGen, Inc., advancing the next generation of oligonucleotide…
VYNE Reports Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an In Vivo Model of Rheumatoid Arthritis
VYN201 demonstrated statistically significant improvement in treatment response for both endpoints at 1mg/kg and 10mg/kg doses…
Recce Pharmaceuticals Announces Positive Safety Data from Fourth Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
Highlights: 10 subjects in cohort four intravenously dosed; RECCE® 327 at 1,000mg, indicating to be…
Immutep’s Efti in Combination with MSD’s Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2nd Line Metastatic Lung Cancer Patients
All enrolled patients were 2nd line metastatic non-small cell lung carcinoma (NSCLC) patients that had…
Prometheus Biosciences Initiates Third Phase 2 Study of PRA023 for Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
– First therapeutic candidate for the treatment of SSc-ILD targeting both key fibrotic and inflammatory…
Biogen Submits Final Protocol for ADUHELM® (aducanumab-avwa) Phase 4 ENVISION Trial to FDA
Confirmatory trial’s completion is expected in an accelerated timeline of four years with patient screening…
Tilray Brands to Announce Third Quarter Fiscal 2022 Financial Results on April 6, 2022
LEAMINGTON, Ontario, March 30, 2022 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray Brands” or the…
CENTOGENE Reports Fourth Quarter and Full Year 2021 Financial Results
– Full Year 2021 Total Revenue Growth of 48%, and 11% in Core Business Segments,…
Cognition Therapeutics Reports Year End 2021 Financial Results and Provides Business Update
– Well capitalized from $52 million IPO and $169 million in grant funding –– Established…